The worst seems over for Teva

The worst seems over for Teva

Source: 
GoinPharma
snippet: 

Teva Pharmaceuticals last week announced it has obtained the FDA approval for Ajovy (Fremanezumab) for migraine prevention. The news boosted its shares. Indeed, many analysts expect the drug to generate annual sales up to $1bn (2021).